Premier Alternatives

Periotherapia

Suita, Japan · Founded 2017 · Privately Held (backing)

Developer of medical treatments designed to tackle intractable diseases. Periotherapia is based in Suita, Japan and was founded in 2017. Its last reported valuation was $16.1 million in Jan 2025. It has raised $14.9 million.

Last reported valuation
$16.1M
Oct 2026
Priced at
—
Total raised
$14.9M
Last round
—

Periotherapia key facts

as of Oct 2026
  • Developer of medical treatments designed to tackle intractable diseases.
  • Periotherapia is valued at approximately $16.1M as of Oct 2026 (last reported valuation).
  • It has raised $14.9M; the latest was Later Stage VC ($4.8M) in Jan 2025.
  • Notable investors include Mitsubishi UFJ Capital, Osaka University Venture Capital, Chushin Venture Capital, Chishima Land, Chishima Real Estate — 9 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$16.1M

Periotherapia's last reported valuation, Jan 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of Periotherapia with a free Private Market View account
  • ·Watch Periotherapia: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Periotherapia funding rounds

No rounds on record

No funding rounds for Periotherapia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Periotherapia valuation

Periotherapia's last reported valuation was $16.1 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.

Periotherapia investors

9 investors are on record for Periotherapia, including Mitsubishi UFJ Capital, Osaka University Venture Capital, Chushin Venture Capital and Chishima Land.

About Periotherapia

Developer of medical treatments designed to tackle intractable diseases. The company's therapies construct a pipeline that makes use of disease-specific antibodies and contributes to early diagnosis and precision medicine using companion diagnostics, enabling health professionals to discover new drugs for breast cancers, heart failure, arteriosclerosis, renal failure and diabetic retinopathy.

Sector
Healthcare
HQ
Suita, Japan
Founded
2017
Employees
12
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.